These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27699719)

  • 1.
    Rahbar K; Bögemann M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):166-167. PubMed ID: 27699719
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Rahbar K et al.
    Yadav MP; Ballal S; Tripathi M; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):168-169. PubMed ID: 27695908
    [No Abstract]   [Full Text] [Related]  

  • 3. Excellent Response to Lower Dose of 177Lu-PSMA-617 in a Metastatic Castration-Resistant Prostate Cancer Patient With a Transplanted Kidney.
    Norouzi G; Aghdam RA; Hashemifard H; Pirayesh E
    Clin Nucl Med; 2019 Jun; 44(6):483-484. PubMed ID: 30829871
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Rahbar K; Ahmadzadehfar H; Boegemann M
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):513-514. PubMed ID: 29164300
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of Hepatic Metastases of Hormone Refractory Prostate Cancer Using Radioligand Therapy With 177Lu-PSMA-617.
    Wei X; Schlenkhoff C; Sopora C; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Nov; 41(11):894-895. PubMed ID: 27607162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exceptional 4-year response to
    Gafita A; Wang H; Tauber R; D'Alessandria C; Weber WA; Eiber M
    Eur J Nucl Med Mol Imaging; 2019 Sep; 46(10):2212-2213. PubMed ID: 31273434
    [No Abstract]   [Full Text] [Related]  

  • 8. [PSMA radioligand therapy in patients with advanced prostate cancer].
    Bögemann M; Herrmann K; Radtke JP; Rahbar K
    Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?
    Gupta M; Karthikeyan G; Choudhury PS; Babu Koyyala VP; Sharma M; Jain P; Talwar V; Singh A; Rawal S
    Cancer Invest; 2020 Sep; 38(8-9):486-492. PubMed ID: 32804008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of short-term dexamethasone on the efficacy of
    Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
    Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT.
    Roll W; Bode A; Weckesser M; Bögemann M; Rahbar K
    Clin Nucl Med; 2017 Feb; 42(2):152-153. PubMed ID: 27922871
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of tumor markers in men with metastatic prostate cancer undergoing [
    Yordanova A; Linden P; Hauser S; Feldmann G; Brossart P; Fimmers R; Essler M; Holdenrieder S; Ahmadzadehfar H
    Prostate; 2020 Jan; 80(1):17-27. PubMed ID: 31579967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of
    Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
    J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
    Kim YJ; Kim YI
    Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617.
    Giesel FL; Cardinale J; Schäfer M; Neels O; Benešová M; Mier W; Haberkorn U; Kopka K; Kratochwil C
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1929-30. PubMed ID: 27342416
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Imperative for Comparative Studies in Nuclear Medicine: Elevating
    Rahbar K; Boegemann M
    J Nucl Med; 2024 Feb; 65(2):224-225. PubMed ID: 38176720
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.